Medicare’s 2026 drug price negotiations under the Inflation Reduction Act aim to lower the cost of expensive medications, ...

The cuts stem from the Inflation Reduction Act, not Trump’s “most favored nation” approach, and apply to what Medicare pays ...

CMS announces billions in savings for Medicare when first and second rounds of negotiations go into effect in 2026 and 2027, ...

WOBURN, Mass., July 31, 2025 /PRNewswire/ -- Azurity Pharmaceuticals, Inc. announced today the availability of BRYNOVIN™ (sitagliptin) oral solution, a dipeptidyl peptidase-4 (DPP-4) inhibitor ...

Expert Rev Endocrinol Metab. 2008;3(6):691-697. Elimination of sitagliptin occurs primarily via renal excretion (79%) and involves active tubular secretion. Sitagliptin is a substrate for human ...

As a new class of OADs, DPP-4 inhibitors have many important advantages over other currently available antidiabetic drugs. Compared with currently available insulin secretagogues, DPP-4 inhibitors, by ...